Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

Arthur J. Atkinson, Wayne A. Colburn, Victor G. DeGruttola, David L. DeMets, Gregory J. Downing, Daniel F. Hoth, John A. Oates, Carl C. Peck, Robert T. Schooley, Bert Spilker

Type: Review

Publication Date: 2001-03-01

Citations: 6251

DOI: https://doi.org/10.1067/mcp.2001.113989

View Publication

Locations

Clinical Pharmacology & Therapeutics - View
PubMed - View

Similar Works

Action	Title	Year	Authors
+	Biomarkers and Surrogate Endpoints	2016	Melissa A. Robb Pamela McInnes Robert M. Califf
+	Biomarkers and Surrogate Endpoints in Monitoring Therapeutic Interventions	2008	Jeffrey K Aronson
+	Biomarkers: Principles, Policies, and Practice	2009	JA Wagner
+ PDF Chat	Significance of biomarkers and surrogate endpoints in preclinical and clinical trials	2007	Katarina Ilić Vesna Kuntić
+ PDF Chat	What are biomarkers?	2010	Kyle Strimbu Jorge A. Tavel
+ PDF Chat	Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?	2002	Chetan Lathia
+	Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.	2007	Marissa Lassere Kent Johnson Maarten Boers Peter Tugwell Peter Brooks Lee S. Simon Vibeke Strand Philip G. Conaghan Mikkel Østergaard Walter P. Maksymowych
+	Comparing and combining biomarkers as principal surrogates for time‐to‐event clinical endpoints	2017	Erin E. Gabriel Michael C. Sachs Peter B. Gilbert
+	Biomarkers and Surrogates in Clinical Studies	2008	Claudio Rigatto Brendan J. Barrett
+	Biomarkers—A General Review	2017	Jeffrey K Aronson R E Ferner
+ PDF Chat	Biomarker definitions and their applications	2018	Robert M. Califf
+	Biomarkers and Surrogate End Points for Fit-for-Purpose Development and Regulatory Evaluation of New Drugs	2006	JA Wagner Subbu Williams Chris Webster
+	Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation	2019	Audrey D. Zhang Joseph S. Ross
+	Optimizing the Use of Biomarkers, Surrogate Endpoints, and Clinical Endpoints for More Efficient Drug Development	2000	Wayne A. Colburn
+	Biomarkers in Health and Disease: Further Knowledge	2015	Rajkumar Rajendram Roshanna Rajendram Vinood B. Patel Victor R. Preedy
+ PDF Chat	Validation of Biomarkers as Surrogates for Clinical Endpoints	2003
+	Randomized Controlled Trials 5: Biomarkers and Surrogates/Outcomes	2021	Claudio Rigatto Brendan J. Barrett
+	Perspectives on Biomarker and Surrogate Endpoint Evaluation	2011	Institute of Medicine
+	Surrogate outcome markers in research and clinical practice	2009	Scott Twaddell
+ PDF Chat	Biomarkers and surrogate endpoints	2005	Jeffrey K Aronson

Works That Cite This (439)

Action	Title	Year	Authors
+ PDF Chat	The Use of Biomarkers in Human Pharmacology (Phase I) Studies	2014	Adam F. Cohen Jacobus Burggraaf Joop van Gerven Matthijs Moerland Geert Jan Groeneveld
+ PDF Chat	Surrogate Markers in Clinical Studies: Problems Solved or Created?	2006	Braden Manns William F. Owen Wolfgang C. Winkelmayer P.J. Devereaux Marcello Tonelli
+ PDF Chat	The meaning of significant mean group differences for biomarker discovery	2021	Eva Loth Jumana Ahmad Chris Chatham Beatriz López Ben Carter Daisy Crawley Bethany Oakley Hannah Hayward Jennifer Cooke Antonia San José Cáceres
+ PDF Chat	A review of phase II trial designs for initial marker validation	2013	Sumithra J. Mandrekar Ming-Wen An Daniel J. Sargent
+ PDF Chat	Mass spectrometry-based multiplexing for the analysis of biomarkers in drug development and clinical diagnostics — How much is too much?	2012	Uwe Christians Jacek Klepacki Touraj Shokati Jost Klawitter Jelena Klawitter
+ PDF Chat	Progression‐free survival in oncology: Caveat emptor!	2018	Troels K. Bergmann Mette Marie Hougaard Christensen Daniel Pilsgaard Henriksen Maija Bruun Haastrup Per Damkier
+ PDF Chat	An efficient algorithm to assess multivariate surrogate endpoints in a causal inference framework	2022	Alvaro J. Flórez Geert Molenberghs Wim Van der Elst Ariel Alonso
+ PDF Chat	BIOMARKERS, TYPES AND ROLE IN PERSONALIZED MEDICINE	2022	А. О. Конради
+ PDF Chat	Spatial process decomposition for quantitative imaging biomarkers using multiple images of varying shapes	2020	ShengLi Tzeng Jun Zhu Amy J. Weisman Tyler Bradshaw Robert Jeraj
+	Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamics in Clinical Pharmacology	2020	Daniel F. B. Wright Chihiro Hasegawa Hesham S. Al‐Sallami

Works Cited by This (10)

Action	Title	Year	Authors
+	Surrogate endpoints: A basis for a rational approach	1992	Jean‐Pierre Boissel Jean‐Philippe Collet P Moleur M. Haugh
+	Surrogate Markers in AIDS: Where Are We? Where Are We Going?	1992	Stephen W. Lagakos Daniel F. Hoth
+ PDF Chat	Efficacy Measures: Surrogates or Clinical Outcomes?	1996	John W. Blue Wayne A. Colburn
+	Meta-analysis for the evaluation of potential surrogate markers	1997	Michael J. Daniels Michael D. Hughes
+	Surrogate End Points in Clinical Trials: Are We Being Misled?	1996	Thomas R. Fleming
+ PDF Chat	Surrogate End Points, Health Outcomes, and the Drug-Approval Process for the Treatment of Risk Factors for Cardiovascular Disease	1999	Bruce M. Psaty
+	Statistical validation of intermediate endpoints for chronic diseases	1992	Laurence S. Freedman Barry I. Graubard Arthur Schatzkin
+	ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKER	1997	D. Y. Lin Thomas R. Fleming Victor De Gruttola
+	Surrogate endpoints in clinical trials: Definition and operational criteria	1989	Ross L. Prentice
+	Evaluating surrogate markers.	1995	Michael D. Hughes Victor DeGruttola Seth L. Welles